Merck has issued an update on the development programs for vorapaxar, extended release niacin/laropirprant(MK524A,Tredaptive) and anacetrapib in association with the European Society of Cardiology (ESC) meeting in Munich, Bavaria. ...
Tags: Merck, vorapaxar, HPS2-THRIVE